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ABSTRACT
Objective The English Diabetic Eye Screening (DES) 
programme recommends patients with M1 diabetic 
maculopathy to be referred to hospital eye services. DES 
uses flash fundus photography as the reference standard 
for maculopathy grading. We compared multicolour versus 
non- stereoscopic fundus photography at identifying M1 
maculopathy, with spectral domain optical coherence 
tomography (SD- OCT) identifying macular thickening.
Methods and analysis This cross- sectional study 
included 345 patients with R1M1 referred from DES and 
reviewed in secondary care with fundus photographs, 
multicolour and SD- OCT. Maculopathy was graded based 
on DES exudate criteria on both multicolour and fundus 
photography in a blind fashion by two independent 
graders. Macular thickness was ascertained on SD- OCT.
Results Intergrader agreement on grading 
maculopathy using fundus photography (Cohen’s 
κ=0.91) and multicolour (Cohen’s κ=0.82) was ‘almost 
perfect’. Agreement between fundus photography and 
multicolour on grading maculopathy (Cohen’s κ=0.76) 
was ‘substantial’. Compared with fundus photography, 
multicolour had sensitivity of 87% (95% CI 81% to 93%) 
and specificity of 90% (95% CI 87% to 94%) in detecting 
M1 maculopathy. SD- OCT identified 84 eyes with macular 
thickening, 47 of which were graded as M0 by fundus 
photography. 5 eyes with exudates and severe macular 
oedema requiring urgent intervention were also missed 
on fundus photography but not on multicolour. Multicolour, 
when complemented by SD- OCT, did not miss any clinically 
significant macular oedema.
Conclusion Multicolour integrates synergistically 
in a single platform with SD- OCT providing effective 
monitoring of M1 diabetic maculopathy. The need for 
fundus photography is eliminated by multicolour/SD- OCT 
in dedicated R1M1 virtual clinics not requiring parallel 
diabetic retinopathy grading.
INTRODUCTION
In the UK, up to one- third of adults with 
diabetes have concurrent diabetic eye 
disease.1 2 It is the most common cause of 
sight loss among working age adults.3 There-
fore, the English National Health Service 
Diabetic Eye Screening (DES) programme 
offers diabetic eye screening for individuals 
with diabetes aged 12 years and over.3
Diabetic maculopathy manifesting as 
diabetic macular oedema (DMO) is the 
leading cause of blindness among the 
population with diabetes.4 The main patho-
physiological factor is thought to be the 
disruption of blood–retina barrier secondary 
to long- term hyperglycaemic insult and 
inflammation, which leads to leakage of 
plasma into the neurosensory retina resulting 
in DMO and hard exudates in the macula.4 5 
The hard exudates are composed of lipids and 
plasma proteins accumulating mainly at the 
outer plexiform layer.6–8
The DES defines the macula as the area of 
the retina confined by a circle with the fovea 
at its centre and touching the temporal edge 
of the optic disc.9 The DES recommends 
Key messages
What is already known about this subject?
 ► Diabetic retinopathy is the most common cause of 
sight loss among working age adults. The English 
NHS Diabetic Eye Screening (DES) programme rec-
ommends patients with M1 diabetic maculopathy, 
diagnosed using flash fundus photography, to be 
referred to hospital eye services.
What are the new findings?
 ► This is a cross- sectional study comparing fundus 
photography (FP) with MultiColor (MC) integrated 
with SD- OCT in diagnosing M1 maculopathy. As com-
pared to FP, MC has excellent sensitivity and spec-
ificity in diagnosing M1 maculopathy. Furthermore, 
MC integrates synergistically in a single platform 
with SD- OCT providing effective monitoring of M1 
diabetic maculopathy, identifying potential patients 
requiring treatment with the modern pharmacologic 
agents such as vascular endothelial growth factor 
inhibitors (anti- VEGF), eliminating the need for FP in 
dedicated R1M1 virtual clinics not requiring parallel 
diabetic retinopathy grading.
How might these results change the focus of 
research or clinical practice?
 ► The DES criteria for maculopathy grading using non- 
stereoscopic FP is becoming increasingly less rele-
vant in an era of anti- VEGF where OCT is becoming 
more important in diagnosing diabetic maculopathy. 
This study does not provide a direct evaluation of MC 
imaging and FP within the DES programme.
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patients with M1 diabetic maculopathy to be referred to 
the hospital eye services (HES).3 The DES definition of 
M1 maculopathy includes any exudates within one disc 
diameter (1DD) of the fovea, retinal thickening within 
1DD of the fovea or a group of exudates that covers an 
area that is greater than or equal to half the disc area, all 
within the macula.9 10
The DES uses flash colour and red- free fundus photog-
raphy (FP) as the reference standard for maculopathy 
grading.11 Colour FP is an imaging modality which 
closely concords with clinical examination findings when 
using an ophthalmoscope or slit- lamp biomicroscope. 
However, in the past decade, different systems based 
on confocal scanning laser ophthalmoscopy (SLO) 
for fundus imaging have been developed producing 
‘pseudo- colour’ composites. Examples of these systems 
include Optos wide- field SLO (Optos, Dunfermline, UK) 
using green (λ=532 nm) and red (λ=633 nm) laser wave-
lengths12; Nidek F-10 confocal SLO (Nidek, Fremont, 
California, USA) which uses infrared (λ=790 nm), 
red (λ=660 nm), green (λ=532 nm) and blue (λ=490 
nm) laser wavelengths13; multicolour (MC) confocal 
SLO imaging (Heidelberg Engineering, Heidelberg, 
Germany) which uses three simultaneously acquired 
laser reflectance images using infrared (λ=815 nm), 
green (λ=518 nm) and blue (λ=486 nm) wavelengths.14 
Fundus images obtained using systems such as MC can 
appear strikingly different when compared with the FP, 
however, some macular pathologies appear more distinct 
on the MC.14 15
The additional benefit of MC system is that it is integrated 
with spectral domain optical coherence tomography (SD- 
OCT) in a single platform. This potentially allows for a 
more comprehensive evaluation of diabetic maculopathy, 
based on detection of exudates and retinal thickening, 
when compared with non- stereoscopic FP alone. Indeed, 
there is a good correlation between macular fluorescein 
angiographic leakage and visual acuity with OCT features 
of diabetic maculopathy.16 17
In this study, first, we aim to compare MC versus FP 
at identifying M1 maculopathy based on presence of 
macular exudates. Second, we endeavour to identify M1 
maculopathy based on retinal thickening with SD- OCT, 
which is undetectable on non- stereoscopic FP. Finally, we 
compare the merits of integration of MC and SD- OCT 
versus FP when evaluating M1 maculopathy in dedicated 
R1M1 virtual clinics not requiring parallel diabetic reti-
nopathy grading.
METHOD
Population and image acquisition
This is a cross- sectional study of 187 patients with diabetes 
(367 eyes) who were monitored in virtual macular clinics 
between 1 January 2012 and 1 January 2013 after an initial 
referral from the English DES programme to HES for 
further evaluation of R1M1 grading (figure 1). Mydriasis 
was achieved 30 min after instillation of preservative- free 
tropicamide 1% and phenylephrine 2.5% eye drops. A 
Zeiss Visucam Pro NM non- mydriatic fundus camera was 
used to obtain FPs consisting of 30° and 45° colour and 
red- free images centred on the fovea. Heidelberg Spec-
tralis (Heidelberg Engineering, Heidelberg, Germany) 
was used to acquire 30° MC images centred on the fovea 
as well as SD- OCT scans. Specifically, we used the built- in 
Fast Macula protocol of 20°×15° 6×6 mm volume centred 




FP images were viewed using Zeiss VISUPAC software 
with its available image manipulation tools applied if 
needed. MC (including the individual blue, green and 
infrared reflectance images) and SD- OCT images were 
viewed using Heidelberg Eye Explorer with its image 
manipulation tools used as necessary.
The MC and FP images were delinked. The diabetic 
maculopathy was graded based on exudate criteria as 
described by the DES on both MC and FP in a blind 
fashion independently by two graders (OK and SP). 
Infrared reflectance, green reflectance, blue reflectance 
and MC composite were assessed individually to decide 
on the presence of exudates (figure 2). An image was 
deemed ungradable if the detail of the third order retinal 
vessels from the superior and inferior vascular arcades 
was not discernible.
Figure 1 Flowchart of study participants. FP, fundus 
photography; MC, multicolour; OCT, optical coherence 
tomography.
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On SD- OCT, an exudate was defined as a homogenous 
hyper- reflective focus of ≥63 µm at, or internal to the 
outer plexiform layer with no inner hyporeflectivity. M1 
maculopathy based on exudate criteria as outlined by the 
DES was not assessed systematically using SD- OCT as the 
spacing between the B- scans was >63 µm and the scan 
did not cover the entire macular as defined by the DES. 
However, any exudate seen on SD- OCT was recorded and 
correlated with FP and MC findings.
Macular thickness criteria
Macular oedema and thickness were ascertained on 
SD- OCT and retinal thickness maps on Heidelberg Eye 
Explorer by two independent graders (OK and SP). 
The thickness map was centred at the fovea and the 
retinal boundaries were defined between the internal 
limiting membrane and the Bruch’s membrane/retinal 
pigment epithelium complex—correction of the auto-
mated segmentation was made if needed. We defined 
abnormally increased macular thickening as central 
subfield thickness (CST) of ≥320 µm for men and ≥310 
µm for women or thickening of ≥360 µm in any of the 
Early Treatment Diabetic Retinopathy Study (ETDRS) 
grid inner sectors on Heidelberg Spectralis SD- OCT as 
described elsewhere.18 19 ‘Clinically significant macular 
oedema’ (CSMO) on SD- OCT was defined as spongiform 
or multicystoid retinal thickening of ≥370 µm in the CST 
or of >390 µm in any of the ETDRS grid inner sectors.19 
A correction factor of +70 µm was used to convert Stratus 
OCT (Carl Zeiss, Oberkochen, Germany) reported values 
for retinal thickening in the literature to equivalent 
Heidelberg Spectralis SD- OCT.20 Eyes with other causes 
of increased macular thickness such as vitreomacular 
traction, epiretinal membrane and choroidal neovascu-
larisation were excluded. Any disagreements between the 
two graders (OK and SP) were resolved by a third grader 
(MMDF).
Patient and public involvement
Patients were not directly involved in the design of this 
study.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statis-
tics for Windows, V.22. The tests were two tailed with type 
I error set at α=0.05. To ascertain the level of agreement 
between the two graders (OK vs SP) and the two different 
imaging modalities (MC vs FP), Cohen’s κ coefficient was 
calculated.21 FP was set as the reference standard and 
the sensitivity, the specificity, the positive predictive value 
and the negative predictive value of MC at detecting M1 
maculopathy as per DES were calculated with 95% CIs.
RESULT
The study included 345 eyes with gradable images in all 
three modalities (figure 1). Either FP or MC image was 
missing from five eyes. There were four ungradable MC 
images and eight ungradable FP images. The rate of M1 
diabetic maculopathy in this cohort was 32%, and 35% 
on FP and MC, respectively (table 1).
Intergrader and intermodality level of agreement in detecting 
M1 diabetic maculopathy based on exudate criteria of DES
The levels of agreements are listed in table 2. There 
was an ‘almost perfect’ intergrader (OK vs SP) level 
of agreement in detecting M1 maculopathy on FP 
(Cohen’s κ=0.91; p<0.0001). There was a ‘substantial’ 
intergrader (OK vs SP) level of agreement in detecting 
M1 maculopathy on MC (Cohen’s κ=0.82; p<0.0001). 
The intermodality level of agreement between MC and 
FP in detecting M1 maculopathy was also ‘substantial’ 
(Cohen’s κ=0.76; p<0.0001 for OK and Cohen’s κ=0.72; 
p<0.0001 for SP). Furthermore, once the final grading 
for each patient was agreed on FP and MC, the intermo-
dality level of agreement remained ‘substantial’ (Cohen’s 
κ=0.76; p<0.0001).
The diagnostic performance of MC in detecting M1 diabetic 
maculopathy based on exudate criteria of DES compared with 
FP as reference standard
Compared with the FP reference standard, the MC had 
sensitivity of 87% (95% CI 81% to 93%), specificity of 
90% (95% CI 87% to 94%), positive predictive value of 
80% (95% CI 73% to 88%) and negative predictive value 
of 94% (95% CI 91% to 97%) in detecting M1 maculop-
athy. In the peripheral macula, beyond 1DD of the fovea, 
where M1 is defined by group of exudates rather than 
any exudates, MC had sensitivity of 97% (95% CI 92% to 
100%), specificity of 99% (95% CI 98% to 100%), posi-
tive predictive value of 95% (95% CI 87% to 100%) and 
negative predictive value of 99% (95% CI 99% to 100%) 
for detection of M1 maculopathy.
Figure 2 Visualisation of exudates on different imaging 
modalities. Macular exudates on multicolour composite (A), 
green reflectance channel (B), infrared reflectance channel 
(C), fundus photography (FP) (D) and red- free FP (E). The 
green reflectance channel is the main contributor to exudate 
visualisation on the multicolour composite image. Please 
note the absence of exudate on infrared reflectance channel 
as it images deeper retinal structures.
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Macular thickening on SD-OCT
Twenty- four per cent (n=84) of eyes had a degree of 
foveal or parafoveal macular thickening based on criteria 
described above (table 1). Interestingly, 70% and 67% 
of eyes with M1 maculopathy on FP and MC, respec-
tively, demonstrated no macular thickening on SD- OCT. 
Among the eyes with OCT macular thickening, 56% and 
50% had no M1 maculopathy on FP and MC, respectively, 
and 44% of times had no M1 maculopathy either on FP 
or on MC.
CSMO based on SD-OCT
Eighteen eyes had CSMO on OCT, characterised by 
spongiform or cystoid retinal thickening causing CST 
≥370 µm or thickening >390 µm of any of the ETDRS 
grid inner sectors (table 1). MC and FP did not detect 
M1 maculopathy in one (0.6%) and five eyes (28%), 
respectively.
Five patients (1.4%) had a CST ≥400 µm, of whom only 
one had no M1 maculopathy on MC but four had no M1 
maculopathy on FP (figure 3).
Detection of exudates on SD-OCT
M1 maculopathy was not assessed systematically using 
SD- OCT. However, there were 19 cases of an exudate 
detected on SD- OCT within the 1DD of the macula, 10 
of which were also detected on MC, but not on FP. In 
contrast, there were only three cases where an exudate 
was detected both on SD- OCT and FP but not on MC.
Table 1 Clinical characteristics
M1 diabetic maculopathy (DES exudate criteria)
  On FP, n (%) 109 (32)
  On MC, n (%) 119 (35)
M1 diabetic maculopathy (DES exudate criteria) without 
macular thickening on SD- OCT
  FP 76
  MC 80
Macular thickening on SD- OCT
  Thickened CST (male ≥320 µm and female 
≥305 µm)
40
  Thickened inner sector of ETDRS grid 
(≥360 µm)
70
  Thickened CST and/or inner sector 84
  Thickened CST and/or inner sector but no 
exudates on FP
47
  Thickened CST and/or inner sector but no 
exudates on MC
42
  Thickened CST and/or inner sector but no 
exudates on FP or MC
37
‘Clinically significant macular oedema’
  Total 18
  Missed by MC 1
  Missed by FP 5
Other macular abnormalities
  Vitreomacular traction 6
  Subfoveal pigment epithelial detachment 1
  Epiretinal membrane 4
  Central serous chorioretinopathy 1
CST, central subfield thickness; DES, Diabetic Eye Screening; 
ETDRS, Early Treatment Diabetic Retinopathy Study; FP, fundus 
photography; MC, multicolour; SD- OCT, spectral domain optical 
coherence tomography.
Table 2 Intergraders and intermodality level of agreement 
grading M1 maculopathy as defined by DES
Cohen’s κ coefficient
Grading on FP: OK vs SP 0.91 (p<0.0001)
Grading on MC: OK vs SP 0.82 (p<0.0001)
OK grading FP vs MC 0.76 (p<0.0001)
SP grading FP vs MC 0.72 (p<0.0001)
Overall grading FP vs MC 0.76 (p-<0.0001)
DES, Diabetic Eye Screening; FP, fundus photography; MC, 
multicolour.
Figure 3 Macular exudate and thickening are evident on 
multicolour (B) and SD- OCT (C), but missing from fundus 
photo (A). There is a linearly shaped cluster of exudates on 
multicolour (B) that are missed on fundus photo (A), even at 
high magnification (inset). Two cross- sectional OCT scans 
are shown in (C), with its near infrared fundus registration 
image on the left: X, centred on the fovea, shows cystoid 
macular oedema; Y, is a line that cross- sections one of 
the exudates, marked with the yellow arrow, seen on the 
multicolour image (B) but not on the fundus photo (A) or 
on the infrared reflectance channel (C). SD- OCT, spectral 
domain optical coherence tomography.
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DISCUSSION
In this study, we demonstrated that MC reliably detects 
M1 maculopathy with acceptable sensitivity and spec-
ificity, with a ‘substantial’ interobserver agreement, 
when compared with the current reference standard. 
Moreover, when synergistically integrated into a single 
platform with SD- OCT in a dedicated R1M1 virtual clinic 
not requiring parallel diabetic retinopathy grading, MC 
performs superior to FP in detecting and monitoring M1 
maculopathy as described by DES.
Overall, the sensitivity and specificity of the MC are 
clinically acceptable and with a negative predictive value 
of 94% (95% CI 91% to 97%) in combined periph-
eral and central M1 maculopathy. However, when it 
comes to peripheral M1 maculopathy, beyond 1DD of 
the fovea, where DES criteria for M1 require the pres-
ence of discrete and grouped exudates, rather than any 
exudates, the MC sensitivity and specificity are excellent. 
Furthermore, MC has a comparable level of intergrader 
agreement to FP. Most of disagreements between MC 
and FP arose secondary to a small central exudate not 
being detected by one of the modalities due to the 
exudate being singular and small. In the case of MC, it 
could be due to its confocal nature and its thin focusing 
plane missing the small exudate. However, the group of 
exudates at the periphery was almost always detected by 
both of the modalities. Nevertheless, it must be remem-
bered that FP, which is currently the reference standard 
for detecting M1 maculopathy within the DES, can miss 
exudates as identified on SD- OCT as shown here and 
elsewhere.14 Therefore, the true sensitivity and specificity 
of MC in detecting M1 maculopathy based on exudates 
criteria are unknown and may be redefined by OCT.
One of the most pertinent issues that arose in this study 
was the fact that more than two- thirds of the patients with 
M1 maculopathy according to exudate criteria on FP or 
MC had no macular thickening on SD- OCT. Conversely, 
one- fifth of patients with no signs of maculopathy on 
non- stereoscopic FP or MC had some degree of macular 
thickening based on SD- OCT. Perhaps more worryingly, 5 
out of 18 patients with CSMO were missed by FP, whereas 
only one was missed on MC. Missing CSMO undermines 
the utility of FP as a screening tool for detection of macu-
lopathy.
After the landmark ETDRS,22 grid/focal laser photo-
coagulation had been the first- line therapy for DMO 
for a number of years. However, since the advent of new 
pharmacological therapeutics in the form of intravitreal 
anti- vascular endothelial growth factor (anti- VEGF), the 
laser photocoagulation has been largely superseded by 
anti- VEGF therapy as the first- line therapy for central 
involving DMO.23 24
In the era of anti- VEGF therapy for DMO, along with 
visual acuity, the central retinal thickness is one of the 
most important quantitative factors considered for treat-
ment decision- making in the majority of clinical trials.24 
This renders the current DES grading criteria for defini-
tion of diabetic maculopathy based on central exudates 
with limited utility. In fact, the National Institute for 
Health and Care Excellence (NICE) guidelines for the 
use of anti- VEGF for DMO do not take into account 
the presence of exudates.25 26 Worryingly, the FP failed 
to identify a significant number of patients with CSMO. 
Worryingly, of the five individuals who met the CST 
criteria for treatment of DMO with anti- VEGF as per 
NICE guidelines,25 26 only four were identified as having 
M1 maculopathy based on FP.
In our study, while 32% of the 345 eyes assessed in 
this study had M1 grading by FP criteria, only 1.4% met 
the criteria for anti- VEGF therapy as outlined by NICE 
guidelines. The prevalence of diabetic maculopathy is 
increasing in the UK.27 28 The current DES- based classi-
fication and referral pathway for diabetic maculopathy 
may need refinement to adapt to the anti- VEGF era. If 
multimodality imaging inclusive of OCT is introduced at 
the point of referral from screening and applied in any 
subsequent monitoring scheme, patients may be spared 
unnecessary reviews in secondary care and be safely 
discharged back from the HES to the DES programme.
Although singular central exudates on their own are 
largely irrelevant in terms of treatment decision- making 
for DMO, detection of peripheral group of exudates may 
be important in treatment decision- making. This is the 
group MC had very high positive and negative predictive 
values for. These patients may not have central involving 
DMO to be eligible for anti- VEGF treatment but they can 
benefit from focal laser photocoagulation.24 29 The rela-
tive indication for focal laser can be considered in focally 
grouped microaneurysms and leaking capillaries, which 
may delay or prevent conversion into central involving 
DMO.24
A weakness of this study is that it does not provide a 
direct evaluation of MC imaging and FP within the DES 
programme. Our non- mydriatic fundus camera is a 
different model of the cameras used by our local DES 
programme. Moreover, simultaneous MC and FP grading 
would be required at the point of screening. Several 
patients monitored in the HES diabetic maculopathy 
virtual clinics had a considerable time lapse from the 
initial DES referral. The unexpected low prevalence of 
eyes with M1 grading in these clinics, while reflecting 
inadequate discharge policies, provided the strength for 
MC false- positive testing in our study.
In conclusion, the sensitivity and specificity of MC 
are comparable with that of FP in detecting M1 macu-
lopathy, especially where peripheral group of exudates 
is concerned. The relevance of central exudates causing 
M1 maculopathy as detected by FP is largely diminished 
in the era of anti- VEGF therapy. Furthermore, FP can 
dangerously miss DMO and overburdens the secondary 
care with stable patients who can be safely followed up 
by DES. Detection of peripheral group of exudates not 
causing central involving DMO may still be relevant, 
as focal laser photocoagulation of leaking microaneu-
rysms and capillaries may reduce the chance of central 
involving DMO. MC only detects peripheral group of 
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exudates reliably but integrates synergistically in a single 
platform with SD- OCT to provide effective monitoring of 
M1 diabetic maculopathy. The need of FP is eliminated 
by MC/SD- OCT in dedicated R1M1 virtual clinics not 
requiring parallel diabetic retinopathy grading. Inte-
grated MC/SD- OCT has the potential to reduce the 
burden on the overstretched secondary care by reducing 
the number of patients who do not require any treatment 
for their diabetic maculopathy and who can be safely 
followed up in the community.
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